EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Multicenter, randomized phase II trial of multiple doses of lodenosine in combination with stavudine and indinavir in antiretroviral-naive HIV-infected adults



Multicenter, randomized phase II trial of multiple doses of lodenosine in combination with stavudine and indinavir in antiretroviral-naive HIV-infected adults



Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 39: 516




(PDF 0-2 workdays service: $29.90)

Accession: 035349983

Download citation: RISBibTeXText



Related references

Safety and efficacy of lodenosine in combination with stavudine and indinavir in antiretroviral naive, HIV-infected adults Association with severe hepatotoxicity. Antiviral Research 51(1): 26-27, July, 2001

Combination therapy with stavudine , lamivudine and indinavir in antiretroviral naive and experienced HIV infected patients. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 37: 263, 1997

Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. Journal of Acquired Immune Deficiency Syndromes 32(1): 18-29, 2003

The VIRGO study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1-infected adults. Antiviral Therapy 5(4): 267-272, 2001

Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. JAMA 292(2): 180-189, 2004

Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. JAMA 285(9): 1155-1163, 2001

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292(2): 191-201, 2004

A phase II open-label, randomized study of the triple combination of Indinavir, zidovudine and didanosine versus Indinavir alone and zidovudine/didanosine in antiretroviral naive patients. INFECTIOUS DISEASES SOCIETY OF AMERICA [Author], NATIONAL INSTITUTES OF HEALTH [Author], CENTERS FOR DISEASE CONTROL AND PREVENTION [Author] 3rd Conference on retroviruses and opportunistic infections : 90, 1996

Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial. Journal of Acquired Immune Deficiency Syndromes 62(2): 171-179, 2013

Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy: a phase I/II, randomized trial. Aids 28(12): 1769-1781, 2015

A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults. Antiviral Therapy 8(4): 279-287, 2003

A open-label, randomized, comparative study of stavudine + didanosine + indinavir versus d4T + ddI + nevirapine in treatment of HIV-infected naive patients. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 40: 280, 2000

A phase II randomized study of the virologic and immunologic effect of zidovudine + stavudine versus stavudine alone and zidovudine + lamivudine in patients with >300 CD4 cells who were antiretroviral naive (ACTG 298). Aids Research and Human Retroviruses 18(10): 699-704, 2002